{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:04:39Z","timestamp":1790053479961,"version":"4.0.1"},"reference-count":127,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Center for Lung Research","id":[{"id":"https:\/\/ror.org\/03dx11k66","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/03dx11k66","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The 7-year update of the phase 3 CROWN study is the most impressive milestone in anaplastic lymphoma kinase (ALK)+ non-small-cell lung cancer (NSCLC) since the discovery of the oncogene 20 years ago and inaugurates an entire new paradigm. The progression-free survival (PFS) plateau at a high level &gt; 50%, with an estimated very low annual progression rate &lt; 2% after the third year, suggests that lorlatinib can inactivate the disease in most patients. The complete abrogation of on-target resistance abolishes ALK tyrosine kinase inhibitor (TKI) sequencing and will seriously impact future drug development. In the new era of extraordinary drug efficacy, the design of clinical trials, pathways of marketing authorization, and dosing optimization policies will also need to be reconsidered. Lorlatinib will dominate the therapeutic landscape of ALK+ NSCLC until the advent of combination therapies, which are the most reasonable next step. Further strengthening of the ALK blockade with additional ALK-directed drugs could likely eliminate the small residual \u201cleak\u201d of late off-target resistance after the third year, while combination with emerging neoantigen-directed immunotherapies may also help control the highly aggressive and more immunogenic early-progressing tumors and facilitate cure of the disease. Universal state-of-the-art DNA\/RNA NGS for newly diagnosed NSCLC is now imperative to identify and treat all ALK+ patients according to the latest therapeutic advances, which will hopefully soon also spread to earlier stages and other oncogenic drivers.<\/jats:p>","DOI":"10.3390\/cancers18183044","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:03Z","timestamp":1789995003000},"page":"3044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Management and the New Paradigm for ALK+ NSCLC After CROWN"],"prefix":"10.3390","volume":"18","author":[{"given":"Shuo","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT) Heidelberg, a Partnership Between the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69126 Heidelberg, Germany"},{"name":"Department of Translational Pulmonology, Translational Lung Research Center at Heidelberg University Hospital, German Center for Lung Research (DZL), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT) Heidelberg, a Partnership Between the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69126 Heidelberg, Germany"},{"name":"Department of Translational Pulmonology, Translational Lung Research Center at Heidelberg University Hospital, German Center for Lung Research (DZL), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fan, L., Feng, Y., Wan, H., Shi, G., and Niu, W. (2014). Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review an d Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100866"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sabir, S.R., Yeoh, S., Jackson, G., and Bayliss, R. (2017). EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers, 9.","DOI":"10.3390\/cancers9090118"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.18632\/oncotarget.26886","article-title":"Defining molecular risk in ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2019","journal-title":"Oncotarget"},{"key":"ref_5","unstructured":"Hendriks, L.E., Cortiula, F., Mariamidze, E., Martins Branco, D., Passaro, A., Reguart, N., and Reck, M. (2026, August 29). ESMO Oncogene-Addicted Non-Small Cell Lung Cancer Living Guideline v1. 3. Available online: https:\/\/www.esmo.org\/guidelines\/living\u2013guidelines\/esmo\u2013living\u2013guideline\u2013oncogene\u2013addicted\u2013metastatic\u2013non\u2013small\u2013cell\u2013lung\u2013cancer."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: Precision Medicine Takes on Drug Resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Elsayed, M., and Christopoulos, P. (2021). Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020080"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lun g cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_9","unstructured":"Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J., Chirieac, L.R., D\u2019Amico, T.A., DeCamp, M.M., Dilling, T.J., and Dobelbower, M. (2017). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2018, National Comprehensive Cancer Network."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1158\/1078-0432.CCR-17-2588","article-title":"Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Posit ive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103103","DOI":"10.1016\/j.ebiom.2020.103103","article-title":"Longitudinal therapy monitoring of ALK-positive lung cancer by combine d copy number and targeted mutation profiling of cell-free DNA","volume":"62","author":"Dietz","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41698-021-00239-3","article-title":"Early identification of disease progression in ALK-rearranged lung can er using circulating tumor DNA analysis","volume":"5","author":"Angeles","year":"2021","journal-title":"npj Prec. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41416-023-02284-0","article-title":"Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma","volume":"129","author":"Angeles","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cam4.4663","article-title":"Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kin ase inhibitors","volume":"11","author":"Kwon","year":"2022","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.annonc.2026.05.692","article-title":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK- positive non-small-cell lung cancer: 7-year update from the phase III CROWN study","volume":"37","author":"Shaw","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mds242","article-title":"Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer","volume":"24","author":"Shaw","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jtho.2024.09.134","article-title":"MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC","volume":"19","author":"Mok","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"LBA8503","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8503","article-title":"Lorlatinib vs crizotinib in treatment-na\u00efve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","unstructured":"United Nations, Department of Economic and Social Affairs Population Division (2026, August 29). World Population Prospects 2024, Online Edition. Available online: https:\/\/population.un.org\/wpp\/downloads?folder=Standard%20Projections&group=Mortality."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.21037\/tlcr-23-245","article-title":"Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: The tale of the tail","volume":"12","author":"Halmos","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.annonc.2025.12.011","article-title":"PET\/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)","volume":"37","author":"Frost","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e250117","DOI":"10.57264\/cer-2025-0117","article-title":"Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced\/metastatic non-small cell lung cancer: Matching-adjusted indirect comparison","volume":"15","author":"Bauer","year":"2026","journal-title":"J. Comp. Eff. Res."},{"key":"ref_32","first-page":"5","article-title":"Expanding the portfolio of anti-ALK weapons","volume":"4","author":"Mologni","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"139","author":"Nakagawa","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_35","unstructured":"Kuhn, T.S. (1970). The Structure of Scientific Revolutions, University of Chicago Press. [2nd ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhao, M., Shao, T., Shao, H., Zhou, C., and Tang, W. (2024). Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: A systematic review and network meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11916-4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15983","DOI":"10.1002\/cam4.6241","article-title":"A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer","volume":"12","author":"Zheng","year":"2023","journal-title":"Cancer Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100527","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"ref_40","first-page":"100700","article-title":"Alectinib Versus Crizotinib in Asian Patients With Treatment-Na\u00efve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study","volume":"5","author":"Zhou","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S1634","DOI":"10.1016\/j.annonc.2024.10.662","article-title":"629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naive advanced ALK+ non-small cell lung cancer","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_42","first-page":"4035","article-title":"Quality of life and symptom burden in patients with metastatic breast cancer","volume":"24","author":"Ecclestone","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"207\u2013216, discussion 216\u2013217","DOI":"10.1016\/S0090-4295(96)00485-2","article-title":"Health-related quality of life among patients with metastatic prostate cancer","volume":"49","author":"Albertsen","year":"1997","journal-title":"Urology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"105014","DOI":"10.1016\/j.oraloncology.2020.105014","article-title":"Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study","volume":"110","author":"Evren","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/bloodadvances.2025018021","article-title":"Prognosis and patterns of progression in smoldering multiple myeloma","volume":"10","author":"Akhlaghi","year":"2025","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01- 2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2026.44.16_suppl.8002","article-title":"Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN)","volume":"44","author":"Zhang","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1200\/JCO.2025.43.16_suppl.8589","article-title":"Depth of response and progression-free survival in patients with advanced ALK-positive non\u2013small-cell lung cancer treated with lorlatinib","volume":"43","author":"Campelo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2022.40.16_suppl.9072","article-title":"Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L","volume":"40","author":"Camidge","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/actr-23-4","article-title":"An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer","volume":"1","author":"Christopoulos","year":"2023","journal-title":"AME Clin. Trials Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"a039537","DOI":"10.1101\/cshperspect.a039537","article-title":"Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine","volume":"11","author":"Tunali","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.21037\/tlcr-24-942","article-title":"Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: A narrative review","volume":"14","author":"Wang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_54","first-page":"225","article-title":"Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach","volume":"38","author":"Sachpekidis","year":"2023","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_55","unstructured":"Sch\u00fctte, W., G\u00fctz, S., and Nehls, W. (2026, August 29). S3 Leitlinie: Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/lungenkarzinom\/."},{"key":"ref_56","unstructured":"National Comprehensive Cancer Network (2026). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer, National Comprehensive Cancer Network."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Johnson","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.21037\/jtd.2018.05.61","article-title":"EML4-ALK V3, treatment resistance, and survival: Refining the diagnosis of ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2018","journal-title":"J. Thor. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-s mall cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/ijc.31275","article-title":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer","volume":"142","author":"Christopoulos","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1073\/pnas.1322892111","article-title":"Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical \u03b2-propeller domain","volume":"111","author":"Richards","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"jcs241505","DOI":"10.1242\/jcs.241505","article-title":"EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilizatio n and accelerated migration through NEK9 and NEK7","volume":"133","author":"Barone","year":"2020","journal-title":"J. Cell Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"evaa228","DOI":"10.1093\/gbe\/evaa228","article-title":"Comparative Genomics within and across Bilaterians Illuminates the Evolutionary History of ALK and LTK Proto-Oncogene Origination and Divers ification","volume":"13","author":"Dornburg","year":"2021","journal-title":"Genome Biol. Evol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2026.44.16_suppl.8503","article-title":"ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC","volume":"44","author":"Lin","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Var iant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced N on-Small Cell Lung Cancer in the Global Phase III ALEX Study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.1160058","article-title":"Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells","volume":"322","author":"Williams","year":"2008","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-20-2853","article-title":"Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged\/TP53-Mutant NSCLC via Noxa Expression","volume":"27","author":"Tanimoto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","article-title":"LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study","volume":"35","author":"Besse","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jtho.2024.09.184","article-title":"MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib \u00b1 Platinum-Pemetrexed","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.21037\/tlcr-21-32","article-title":"Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies","volume":"10","author":"Christopoulos","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_79","first-page":"100534","article-title":"Efficacy and Tolerability of ALK\/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis","volume":"4","author":"Kiedrowski","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hu, D., Hu, Y., Lei, S., Wu, D., and Wang, Y. (2025). MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: A systematic review and meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14145-5"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/JTO.0b013e31827a892c","article-title":"Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer","volume":"8","author":"Browning","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1538-7445.AM2026-5787","article-title":"Abstract 5787: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins an d leads to regression of ALK TKI-refractory tumors","volume":"86","author":"Conery","year":"2026","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2026.44.16_suppl.8517","article-title":"Prophylactic peptide vaccine targeting resistance mutations in advance d ALK-positive lung cancer: Primary analysis from the ARCHER trial","volume":"44","author":"Conroy","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","article-title":"Efficacy of Platinum\/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors","volume":"15","author":"Lin","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/j.annonc.2024.08.1310","article-title":"1253O Phase I\/II ALKOVE-1 study of NVL-655 in ALK+ solid tumours","volume":"35","author":"Drilon","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Elsayed, M., Bozorgmehr, F., Kazdal, D., Volckmar, A.-L., S\u00fcltmann, H., Fischer, J.R., Kriegsmann, M., Stenzinger, A., Thomas, M., and Christopoulos, P. (2021). Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.670483"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2025.7071","article-title":"Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study","volume":"23","author":"Waliany","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"TPS8666","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8666","article-title":"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (A LK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study","volume":"43","author":"Popat","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"B154","DOI":"10.1158\/1535-7163.TARG-23-B154","article-title":"Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors","volume":"22","author":"Lin","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo-[4,3-h]-[2,5,11]-benzoxa-diaza-cyclo-tetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_92","first-page":"248","article-title":"An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer","volume":"14","author":"Samaeekia","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jtho.2025.09.018","article-title":"PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced\/Metastatic ROS1+ NSCLC","volume":"20","author":"Drilon","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","article-title":"NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Murphy, R., Halford, S., and Symeonides, S.N. (2023). Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1144056"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO-25-00788","article-title":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","volume":"43","author":"Yang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa2604461","article-title":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","volume":"395","author":"Zhou","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/JTO.0b013e31826146ee","article-title":"Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer","volume":"7","author":"Foo","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1101\/pdb.prot077842","article-title":"Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse","volume":"2014","author":"Pirazzoli","year":"2014","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/cas.12284","article-title":"Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model","volume":"104","author":"Hayakawa","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_101","first-page":"100645","article-title":"Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib","volume":"5","author":"Cheung","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12.e11","DOI":"10.1016\/j.urolonc.2017.09.004","article-title":"Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma","volume":"36","author":"Raphael","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Maraz, A., Cserhati, A., Uhercsak, G., Szilagyi, E., Varga, Z., Revesz, J., Koszo, R., Varga, L., and Kahan, Z. (2018). Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4209-9"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus Recommendations for Management and Counseling of Adverse Eve nts Associated With Lorlatinib: A Guide for Healthcare Practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107535","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bcp.15924","article-title":"Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report","volume":"90","author":"Kunz","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/cpt.2228","article-title":"Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I\/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer","volume":"110","author":"Chen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.lungcan.2024.107954","article-title":"Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification","volume":"196","author":"Igawa","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/sim.10066","article-title":"Sample size adaptation designs and efficiency comparison with group sequential designs","volume":"43","author":"Cui","year":"2024","journal-title":"Stat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/LCTT.S446878","article-title":"Overcoming Central \u03b2-Sheet #6 (C\u03b26) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3\/b and v5a\/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver","volume":"15","author":"Lee","year":"2024","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"S1050","DOI":"10.1016\/j.annonc.2025.08.2604","article-title":"1980P Tumor mutational burden (TMB) and proliferation as negative prognostic factors for ALK+ lung cancer: First results from the randomized ABP phase II trial","volume":"36","author":"Christopoulos","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41375-026-02984-5","article-title":"From fatal disease to functional cure: 25 years of tyrosine kinase inh ibition in chronic myeloid leukemia","volume":"40","author":"Hochhaus","year":"2026","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patie nts With ALK-Rearranged NSCLC","volume":"19","author":"Cardona","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-24-1417","article-title":"EML4\u2212ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis","volume":"16","author":"Shuldiner","year":"2026","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: Clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00262-021-02981-w","article-title":"Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma","volume":"71","author":"Budczies","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","article-title":"ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer","volume":"4","author":"Mota","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Gaissmaier, L., Elshiaty, M., and Christopoulos, P. (2020). Breaking Bottlenecks for the TCR Therapy of Cancer. Cells, 9.","DOI":"10.3390\/cells9092095"},{"key":"ref_122","unstructured":"Team, R.C. (2026). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_123","unstructured":"Wassmer, G., and Pahlke, F. (2026). rpact: Confirmatory Adaptive Clinical Trial Design and Analysis, R Foundation for Statistical Computing."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/biomet\/68.1.316","article-title":"The asymptotic properties of nonparametric tests for comparing survival distributions","volume":"68","author":"Schoenfeld","year":"1981","journal-title":"Biometrika"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/10543400500265736","article-title":"Sample size computation for two-sample noninferiority log-rank test","volume":"15","author":"Jung","year":"2005","journal-title":"J. Biopharm. Stat."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:24:47Z","timestamp":1790051087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":127,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18183044"],"URL":"https:\/\/doi.org\/10.3390\/cancers18183044","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}